Do cloned mammals skip a reprogramming step?

Article Abstract:

The lesser life span of cloned animals compared to the conventionally bred animals and the abnormalities of the gene expression in their tissues is presented. The skip of essential independent step involved in the reprogramming of cell nuclei during the process of nuclear transfer used to create cloned animals is the reason for these problems.

Cell nuclei, Cell nucleus

---

Genetic rescue of an endangered mammal by cross-species nuclear transfer using post-mortem somatic cells

Article Abstract:

Scientists clone a mouflon by combining cells from a deceased member of the species with enucleated sheep oocytes and implanting them into a sheep foster mother. Researchers believe this is a valid method for increasing the numbers of endangered species.

United Kingdom, Italy, Research and Development in the Physical, Engineering, and Life Sciences, Czech Republic, Poland, Genetic Engineering, Biology, Illustration

---

Allergenicity assessment of genetically modified crops-what makes sense?

Article Abstract:

A detailed analysis of allergenic risks related to genetically modified (GM) crops is required for the safety of allergic consumers. Many tests that are applied to assess allergenicity do not have a profound scientific basis.

Risk factors, Immunoglobulins, Computational biology, Allergens

Similar abstracts:

• Abstracts: Protein analysis on a proteomic scale. A tethered catalysis, two-hybrid system to identify protein-protein interactions requiring post-translational modifications
• Abstracts: Currents: employment testing: the new hot button issue for federal agencies and other legal developments. Roundup of employment-related news
• Abstracts: Dollar slides as fears grow over funding the widening US trade deficit.... Dollar regains composure, but little has changed
• Abstracts: Client expense accounting becomes more complex. Tax aspects of working at home. Charging clients: find the best method to suit your needs - part II.
• Abstracts: Genta sued over NDA withdrawal. Maturing biotechs turn to pharma's markets. Redesigner drugs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.